Drugs / Fluenz Tetra
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Fluenz Tetra | — | 2025-07-14 | europa.eu ↗ |
| Approved | EU (EMA) | Fluenz Tetra | — | 2013-12-04 | europa.eu ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02266992 | Sep 2014 → Jun 2015 | HIV infectious disease | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03104790 | Oct 2017 → Mar 2018 | influenza | Public Health England | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02557802 | Oct 2015 → Jan 2016 | influenza | University of Surrey | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluenz Tetra | “Live attenuated influenza vaccine- Fluenz tetra.” NCT02266992 ↗ |
| Modality | Vaccine | “live attenuated influenza vaccine” NCT02266992 ↗ |
| Route | Intranasal | “Intra-nasal administration of 0.2ml (0.1ml in each nostril).” NCT02266992 ↗ |